Pooled analysis of efficacy and safety of teclistamab in triple-class exposed relapsed or refractory multiple myeloma

Teclistamab is a bispecific antibody targeting B-cell maturation antigen. Pooled analysis of three clinical cohort studies and a retrospective cohort evaluated efficacy and safety of teclistamab in 217 patients with triple-class exposed relapsed or refractory multiple myeloma (TCE RRMM) in the Global Trial cohort. The median age was 65 year and median number of prior lines of therapy was five; 29.0% had high-risk cytogenetics, and 18.9% had extramedullary disease. The median duration of follow-up was 29.5 months. The overall response rate to teclistamab was 66.4%, with complete response in 50.2%. The median duration of response was not reached, whereas the median progression-free survival was 15.6 months and the median overall survival was 29.1 months. In the subset of 52 patients in the Asian Trial cohort, baseline features were similar except for lower body weight. Median follow-up was 26.6 months. ORR was 76.9% with CRR 63.5%, with 24-month DOR, PFS, and OS 67.5%, 59.5%, and 71.4%, respectively. Most common adverse events were cytopenias, cytokine release syndrome, and infections. The authors conclude that teclistamab demonstrated clinically meaningful benefits across diverse patient groups, reinforcing its potential as a standard of care for TCE RRMM.